Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Decrease in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) was the target of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 17,574 shares, a decrease of 48.6% from the October 15th total of 34,177 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average trading volume of 16,714 shares, the short-interest ratio is currently 1.1 days.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently raised its stake in Alzamend Neuro stock. Kingsbury Capital Investment Advisors LLC increased its holdings in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 134.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,329,100 shares of the company’s stock after acquiring an additional 762,367 shares during the quarter. Alzamend Neuro comprises approximately 1.3% of Kingsbury Capital Investment Advisors LLC’s portfolio, making the stock its 18th biggest position. Kingsbury Capital Investment Advisors LLC owned 27.75% of Alzamend Neuro worth $1,595,000 as of its most recent SEC filing. 49.61% of the stock is owned by institutional investors and hedge funds.

Alzamend Neuro Price Performance

NASDAQ ALZN opened at $1.24 on Monday. The stock has a market capitalization of $5.98 million, a PE ratio of -0.54 and a beta of 0.41. The company’s 50 day simple moving average is $1.48 and its two-hundred day simple moving average is $1.44. Alzamend Neuro has a 1 year low of $0.84 and a 1 year high of $2.56.

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last announced its quarterly earnings data on Thursday, September 10th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.12). On average, research analysts anticipate that Alzamend Neuro will post -1.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, August 31st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alzamend Neuro presently has an average rating of “Hold” and an average price target of $28.00.

Read Our Latest Report on Alzamend Neuro

About Alzamend Neuro

(Get Free Report)

Alzamend Neuro is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease and other neuropsychiatric disorders. The company is based in the United States and does not have marketed products. Its pipeline includes AL001, an investigational lithium-based treatment being studied for conditions including Alzheimer’s disease and bipolar disorder, and ALZN002, an investigational cell-based immunotherapy designed to target Alzheimer’s disease. Both programs remain in development, and their safety and effectiveness have not been established.

Featured Articles

Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.